Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhiqiang Meng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3593-6098; OpenAlex author ID A5003930955. Sources: ClinicalTrials.gov.

Their work

Papers
54 (first author 2, last author 20)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
94
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 5 papers · 2014: 2 papers · 2015: 1 paper, 1 trial · 2016: 7 papers · 2017: 4 papers · 2018: 8 papers · 2019: 9 papers · 2020: 4 papers · 2021: 5 papers · 2022: none · 2023: 3 papers · 2024: 1 paper

Papers 50 of 54

  1. Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal aden… Co-author DOI 10.1038/s41392-024-02052-3↗
  2. Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma. Last author DOI 10.1002/ijc.34334↗
  3. Sequential high-intensity focused ultrasound treatment combined with chemotherapy for inoperable pancreatic cancer: a retrospective analysis for prognostic fac… Last author DOI 10.1080/02656736.2023.2278417↗
  4. Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy. Last author DOI 10.3389/fimmu.2023.1275782↗
  5. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Co-author DOI 10.1002/ctm2.467↗
  6. Circulating EVs long RNA-based subtyping and deconvolution enable prediction of immunogenic signatures and clinical outcome for PDAC. Co-author DOI 10.1016/j.omtn.2021.08.017↗
  7. Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study. Last author DOI 10.1080/17474124.2021.1869937↗
  8. A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and Cancer Cells Regulates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-0256↗
  9. Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling. Co-author DOI 10.1186/s12885-021-08158-z↗
  10. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2019-318860↗
  11. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Co-author DOI 10.18632/aging.102638↗
  12. miR-939-5p Contributes to the Migration and Invasion of Pancreatic Cancer by Targeting ARHGAP4. Co-author DOI 10.2147/ott.s227644↗
  13. Serum level of CCL2 predicts outcome of patients with pancreatic cancer. Co-author PMID 32603049↗
  14. Functions and clinical implications of exosomes in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2018.11.001↗
  15. Overexpressed N-fucosylation on the cell surface driven by FUT3, 5, and 6 promotes cell motilities in metastatic pancreatic cancer cell lines. Co-author DOI 10.1016/j.bbrc.2019.02.092↗
  16. Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.01.015↗
  17. ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. Last author DOI 10.1093/carcin/bgz067↗
  18. Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2019/1356264↗
  19. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. Last author DOI 10.1186/s13046-019-1055-9↗
  20. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upreg… Co-author DOI 10.18632/aging.102307↗
  21. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Last author DOI 10.2147/ott.s185424↗
  22. High-intensity focused ultrasound enhances the effect of bufalin by inducing apoptosis in pancreatic cancer cells. Last author DOI 10.2147/ott.s185953↗
  23. Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer. Co-author DOI 10.1002/cam4.1848↗
  24. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. Co-author DOI 10.1155/2018/7343090↗
  25. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. Co-author DOI 10.1177/0300060518800588↗
  26. TAM Infiltration Differences in "Tumor-First" and " ZHENG-First" Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer. Co-author DOI 10.1177/1534735418771193↗
  27. Cancer-Associated Fibroblasts in Pancreatic Cancer: Should They Be Deleted or Reeducated? Co-author DOI 10.1177/1534735418794884↗
  28. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.3233/cbm-181182↗
  29. Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. Co-author DOI 10.3390/ijms19061768↗
  30. Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years. Co-author PMID 29641971↗
  31. Development and Validation of a Nomogram for Predicting Survival in Patients with Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1038/s41598-017-11227-8↗
  32. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. Co-author DOI 10.1186/s12957-017-1175-7↗
  33. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. Last author DOI 10.3233/cbm-170231↗
  34. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. Last author PMID 28123853↗
  35. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Co-author DOI 10.1002/cncr.30057↗
  36. Cyr61-positive cancer stem-like cells enhances distal metastases of pancreatic cancer. Last author DOI 10.18632/oncotarget.12248↗
  37. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Last author DOI 10.18632/oncotarget.13000↗
  38. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.6450↗
  39. Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling. Last author DOI 10.3892/mmr.2016.5471↗
  40. Retrospective analysis of high intensity focused ultrasound combined with S-1 in the treatment of metastatic pancreatic cancer after failure of gemcitabine. Last author PMID 27073725↗
  41. Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts. Last author PMID 27822411↗
  42. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Last author DOI 10.1007/s13277-015-3097-8↗
  43. The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Co-author DOI 10.1038/srep05911↗
  44. Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0096177↗
  45. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting… Last author DOI 10.1016/j.molonc.2012.10.011↗
  46. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Last author DOI 10.1053/j.gastro.2013.07.048↗
  47. Safety evaluation of high-intensity focused ultrasound in patients with pancreatic cancer. Co-author DOI 10.1159/000348530↗
  48. shRNA-mediated Slc38a1 silencing inhibits migration, but not invasiveness of human pancreatic cancer cells. Last author DOI 10.3978/j.issn.1000-9604.2013.09.03↗
  49. MicroRNA targets autophagy in pancreatic cancer cells during cancer therapy. Last author DOI 10.4161/auto.26463↗
  50. High intensity focused ultrasound treatment for patients with advanced pancreatic cancer: a preliminary dosimetric analysis. Co-author DOI 10.3109/02656736.2012.713541↗

Trials 1

  1. Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer Principal investigator NCT02635971↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhen Chen · 35 shared papers, 2011–2021 · strength 2.53
  2. Peng Wang · 20 shared papers, 2011–2023 · strength 1.58
  3. Zhouyu Ning · 13 shared papers, 2016–2024 · strength 1.55
  4. Lianyu Chen · 18 shared papers, 2011–2021 · strength 1.38
  5. Chien‐shan Cheng · 9 shared papers, 2018–2023 · strength 1.16
  6. Luming Liu · 13 shared papers, 2011–2020 · strength 0.74
  7. Liping Zhuang · 8 shared papers, 2013–2023 · strength 0.72
  8. Chao Qu · 8 shared papers, 2014–2021 · strength 0.70
  9. Luming Liu · 10 shared papers, 2013–2019 · strength 0.69
  10. Hao Chen · 9 shared papers, 2014–2019 · strength 0.62
  11. Yehua Shen · 8 shared papers, 2013–2021 · strength 0.62
  12. Shulin Yu · 6 shared papers, 2016–2021 · strength 0.61
  13. Chenyue Zhang · 7 shared papers, 2016–2021 · strength 0.60
  14. Yongqiang Hua · 7 shared papers, 2016–2021 · strength 0.56
  15. Ling Mei Qian · 5 shared papers, 2019–2021 · strength 0.56
  16. Kun Wang · 7 shared papers, 2011–2023 · strength 0.47
  17. Shu Dong Ma · 5 shared papers, 2016–2023 · strength 0.46
  18. Huifeng Gao · 5 shared papers, 2013–2020 · strength 0.40
  19. Yawen Geng · 4 shared papers, 2016–2021 · strength 0.39
  20. Hao Chen · 4 shared papers, 2018–2020 · strength 0.36
  21. Lanyun Feng · 4 shared papers, 2016–2020 · strength 0.35
  22. Xiaoyan Zhu · 4 shared papers, 2011–2024 · strength 0.33
  23. Shenglin Huang · 3 shared papers, 2019–2021 · strength 0.32
  24. Ailing Zhong · 2 shared papers, 2019–2023 · strength 0.32
  25. Qi Qi · 4 shared papers, 2014–2020 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.